RedHill Biopharma recently announced in a press release that the company will be hosting a presentation at the upcoming Jefferies 2015 Global Healthcare Conference. Guy Goldberg, RedHill’s chief business officer, will discuss RedHill’s progress in developing late clinical-stage, proprietary, orally-administered, small molecule drugs to treat inflammatory and gastrointestinal diseases.
Next Wednesday, June 3, at 3:30 pm EDT, Goldberg will present the latest developments on RedHill’s lead medical products for the treatment of inflammatory and gastrointestinal conditions, ranging from Crohn’s disease to gastrointestinal cancers, at the Grand Hyatt Hotel in New York City. Mr. Goldberg’s presentation will be available online through live webcast on RedHill’s website, and will remain archived for a month.
The oral therapy being developed by RedHill to treat Crohn’s disease is RHB-104, a combined antibiotic treatment that was acquired from the Australian company Giaconda in 2010 and is currently being evaluated in a phase III study. The capsule formulation has potent intracellular, antimycobacterial and anti-inflammatory properties, expected to help improve the symptoms of the disease.
First studied by professor Thomas Borody, the efficacy of RHB-104 is based on the increasingly supported belief that Crohn’s disease develops in susceptible patients due to a Mycobacterium avium subspecies paratuberculosis (MAP) infection. As part of the RHB-104 development program, RedHill is also working on a diagnostic exam in collaboration with Quest Diagnostics that can detect the presence of MAP in blood samples.
Last December, the company presented at the Israeli Inflammatory Bowel Disease Society meeting, an event they sponsored in support of the Israeli IBD Society, which is committed to supporting late clinical-stage drugs for the treatment of inflammatory and gastrointestinal conditions. The meeting was used as an opportunity to enhance partnerships and research initiatives regarding both the diagnosis and treatment of IBD.
In addition, RedHill also presented the first data regarding their Crohn’s disease program, and the evaluation of RHB-104 within the MAP US study, which is being conducted in the U.S., Canada, Israel, Australia, New Zealand and Europe. In addition to Crohn’s disease, RHB-104 is also being studied in a phase IIa proof of concept study for multiple sclerosis in Israel, and the company is planning a phase IIa proof of concept study for rheumatoid arthritis.